Hepalink Pharma kicks off $585m Hong Kong listing

By Jonathan Breen
24 Jun 2020

Shenzhen Hepalink Pharmaceutical Group launched its Hong Kong IPO this week, targeting proceeds of HK$4.53bn ($585m).

Hepalink is based in China but operates globally, focusing on high-mortality rate diseases. Its leading drugs — blood thinners Inhixia, Neoparin and Prolongin — are sold in 15 countries and approved in 36.

It already has A-shares trading on the Shenzhen Stock Exchange but is looking to raise ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial